Per Grufman

Board member, responsibilities of the board includes strategic planning and oversight, stakeholder relations, financing, renewing the structure and organisation etc.

Consultant and Advisor working with biotech companies in Europe. Providing expertise in product development, investor relations, business development etc.

Leopard Biosciences develops molecular diagnostics aiming primarily on the point of care market. The company has developed a unique technology based on CRISPR.

Biocrucible is a part of the Sapphiros group and are developing molecular and lateral flow diagnostics. The company has almost 80 staff that are based across two locations in Cambridge. For molecular diagnostics we utilise the unique molten RPA technology that allows us to develop and manufacture very low cost instrument free molecular diagnostics.

Responsibility includes responsibility for POC V&V, Product Life cycle management including investigations as well as product development for molecular assays on the LumiraDx point of care platform.

Cepheid is providing molecular diagnostics assays in all parts of the world. The main strengths of the platform is the ease of use and ability to operate in all types of environments. The R&D team in Sweden consist of 50+ associates focused on developing assays for the GeneXpert platform. The team has developed multiple assays for infectious diseases including work on viruses, bacteria and parasites. I am also responsible for our R&D activities in China. Cepheid is fully owned by Danaher corporation and the use of the Danaher Business System is helping to drive improvements throughout the organization.

Cepheid is developing and marketing molecular diagnostic products based on real time PCR. Responsibilities include Research strategy and guidance of staff.

AbSorber is developing and selling products for the organ transplantation market. Responsibility included Research strategy and guidance of scientific staff, research collaborations, intellectual property issues, Clinical studies, Regulatory affairs etc. I was responsible for the development of the first product the company developed which was used to improve prediction of rejection of transplants. As head of R&D I also participated in meetings with the board of directors as well as meetings with investors and other external partners. Responsibilities also included setting up manufacturing and QC of the companys first product at the site of an external partner. I joined the company as the first employee except for the founders and during my time with AbSorber it grow to become 10+ staff although most of the organization remained virtual and the majority of work including R&D was performed through external collaborations.

Accuro Immunology AB was developing therapeutic cancer vaccines. The first product which was a cell based vaccine was ready to go into safety and toxicity studies. Responsibilities included animal models (mice) and molecular biology, guidance and training of scientific staff working within these areas, work with intellectual property issues, research strategy, financing etc. I was also responsible for reports and presentations to the board and potential investors

PhD Thesis in December 2002